XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma

This study is testing a drug called zanzalintinib (XL092) for people with a rare soft-tissue cancer called leiomyosarcoma that has spread or cannot be removed by surgery. Researchers want to see if this drug can help slow or stop the cancer. **You may be eligible if...** - You are 18 or older - You have been diagnosed with leiomyosarcoma confirmed at a major cancer center - Your cancer has spread or cannot be surgically removed - You have had 1 prior treatment for your cancer (but no more than 2 prior treatments with a type of drug called a tyrosine kinase inhibitor) - Your heart is pumping well (ejection fraction above 50%) - Your blood counts and organ function (liver, kidneys) are within acceptable ranges **You may NOT be eligible if...** - You have already been treated with this drug (XL092) - You recently had chemotherapy or radiation (within the last 4 weeks) - You have serious heart problems, uncontrolled high blood pressure, or had a stroke or heart attack within the past year - You have brain metastases that are not stable - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.